MRK

Merck is an exceptionally profitable, cash-rich business. FY2025 net income of $18.3B on $65.0B revenue is a 28.1% net margin, and return on equity is 34.7% — elite for any sector. The balance sheet is sturdy: $14.6B cash, current assets of $43.5B against $28.3B current liabilities (1.5x), retained earnings of $73.1B and $52.6B of equity. Note the FY2023 net income of just $365M was a one-off: the income statement shows R&D that year spiked to $30,531M (acquired IPR&D), versus $15,789M in 2025 — so true earnings power is the ~$17–18B run-rate of 2024–2025, not the 2023 trough.

The problem is growth. Revenue decelerated from +21.7% (2021→2022) to just +1.3% (2024→2025), and the +8.0% diluted-EPS gain leans on a 2.1% lower share count and margin, not volume. Two filing details temper the quality story. First, operating cash flow fell 23.3% to $16.5B even as net income rose — the balance sheet shows receivables climbing to $11,775M (from $10,278M) and inventories building, so cash conversion weakened. Second, long-term debt jumped 35.7% to $46,750M while Other Intangibles, Net rose from $16,370M to $26,681M — roughly $10B of debt-funded business development to refill the pipeline, even as reported R&D expense was cut 12%. That is classic pre-cliff maneuvering, and the supplied Risk Factors text is pure boilerplate, so the underlying product-concentration/LOE exposure can't be sized from this data.